Literature DB >> 25683848

Lenvatinib improves survival in refractory thyroid cancer.

Susan Mayor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25683848     DOI: 10.1016/S1470-2045(15)70066-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.

Authors:  Anne-Charlotte Dubbelman; Cynthia M Nijenhuis; Robert S Jansen; Hilde Rosing; Hitoshi Mizuo; Shinki Kawaguchi; David Critchley; Robert Shumaker; Jan H M Schellens; Jos H Beijnen
Journal:  Invest New Drugs       Date:  2016-03-28       Impact factor: 3.850

2.  Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer.

Authors:  Renzhi Yu; Minghuan Wang; Xiuli Zhu; Zhe Sun; Aiying Jiang; Huixin Yao
Journal:  Oncol Lett       Date:  2018-09-11       Impact factor: 2.967

3.  Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.

Authors:  Jianwen Hao; Qizhen Peng; Keruo Wang; Ge Yu; Yi Pan; Xiaoling Du; Na Hu; Xuening Zhang; Yu Qin; Huikai Li
Journal:  Biomed Res Int       Date:  2021-07-22       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.